Article

Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease

2022-11-08

Abstract excerpt

<h4>Background: </h4> There is a critical need for novel primary endpoints designed to detect early and subtle changes in cognition in clinical trials targeting the asymptomatic (preclinical) phase of Alzheimer’s disease (AD). The Alzheimer’s Prevention Initiative (API) Generation Program, conducted in cognitively unimpaired individuals at risk of developing AD (e.g., enriched by the apolipoprotein E (APOE) genoty...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d127a880-10b8-5bcd-b8e4-ff8ea1fc84db
DOI: 10.21203/rs.3.rs-2226991/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s diseaseDOI 10.21203/rs.3.rs-2226991/v1Read

Polygenic hazard scores in preclinical Alzheimer disease.Semantic proximity Read

Cognitive Composites for Genetic Frontotemporal Dementia: GENFI-CogSemantic proximity Read

The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.Semantic proximity Read

“Exceptional brain aging” without Alzheimer’s disease: triggers, accelerators, and the net sum gameSemantic proximity Read

Cognitive composites for genetic frontotemporal dementia: GENFI-Cog.Semantic proximity Read

Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies (WeSHARE)Semantic proximity Read

Use of preclinical Alzheimer’s disease trajectories for clinical trial designSemantic proximity Read

Adjudicating mild cognitive impairment due to Alzheimer’s disease as a novel endpoint event in the TOMMORROW prevention clinical trialSemantic proximity Read

Endpoints in preclinical Alzheimer's disease trials.Semantic proximity Read

Mapping U.S. POINTER Cognitive-Slope Gains Onto Predicted Clinical Progression: An External-Cohort Translation Analysis With Exploratory Economic ThresholdsSemantic proximity Read

Age at onset in genetic prion disease and the design of preventive clinical trialsSemantic proximity Read

Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program.Semantic proximity Read